222,505 Shares in Compass Therapeutics, Inc. $CMPX Bought by Wellington Management Group LLP

Wellington Management Group LLP acquired a new position in shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) in the first quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 222,505 shares of the company’s stock, valued at approximately $423,000. Wellington Management Group LLP owned about 0.16% of Compass Therapeutics at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. American Century Companies Inc. bought a new position in Compass Therapeutics during the 1st quarter worth $140,000. Nuveen LLC bought a new position in Compass Therapeutics during the 1st quarter worth $579,000. Deutsche Bank AG bought a new position in Compass Therapeutics during the 1st quarter worth $194,000. Charles Schwab Investment Management Inc. grew its stake in Compass Therapeutics by 4.1% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 297,880 shares of the company’s stock worth $566,000 after buying an additional 11,689 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its stake in Compass Therapeutics by 2.3% during the 1st quarter. Bank of New York Mellon Corp now owns 243,565 shares of the company’s stock worth $463,000 after buying an additional 5,590 shares during the last quarter. 68.43% of the stock is currently owned by institutional investors.

Compass Therapeutics Stock Performance

Shares of CMPX stock opened at $3.49 on Tuesday. Compass Therapeutics, Inc. has a 1 year low of $1.25 and a 1 year high of $4.08. The stock has a fifty day moving average of $2.95 and a two-hundred day moving average of $2.47. The firm has a market capitalization of $482.60 million, a PE ratio of -7.76 and a beta of 1.50.

Compass Therapeutics (NASDAQ:CMPX) last announced its quarterly earnings results on Monday, August 11th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.01). Equities research analysts predict that Compass Therapeutics, Inc. will post -0.36 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on CMPX. Raymond James Financial upgraded Compass Therapeutics to an “outperform” rating and set a $9.00 price objective for the company in a research note on Tuesday, July 1st. D. Boral Capital restated a “buy” rating and set a $32.00 price objective on shares of Compass Therapeutics in a research note on Tuesday, August 12th. Finally, Guggenheim boosted their price target on Compass Therapeutics from $10.00 to $12.00 and gave the stock a “buy” rating in a research report on Tuesday, August 12th. One analyst has rated the stock with a Strong Buy rating and nine have given a Buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $12.89.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.